RU2166320C2 - Антигипертриглицеридемическая композиция (варианты), способ ее получения, способ лечения или профилактики гипертриглицеридемии - Google Patents

Антигипертриглицеридемическая композиция (варианты), способ ее получения, способ лечения или профилактики гипертриглицеридемии Download PDF

Info

Publication number
RU2166320C2
RU2166320C2 RU95117068/14A RU95117068A RU2166320C2 RU 2166320 C2 RU2166320 C2 RU 2166320C2 RU 95117068/14 A RU95117068/14 A RU 95117068/14A RU 95117068 A RU95117068 A RU 95117068A RU 2166320 C2 RU2166320 C2 RU 2166320C2
Authority
RU
Russia
Prior art keywords
substituted
group
oxo
tetrahydro
hypertriglyceridemia
Prior art date
Application number
RU95117068/14A
Other languages
English (en)
Russian (ru)
Other versions
RU95117068A (ru
Inventor
Сугияма Ясуо
Юкимаса Хидефуми
Original Assignee
Такеда Кемикал Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Кемикал Индастриз, Лтд. filed Critical Такеда Кемикал Индастриз, Лтд.
Publication of RU95117068A publication Critical patent/RU95117068A/ru
Application granted granted Critical
Publication of RU2166320C2 publication Critical patent/RU2166320C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU95117068/14A 1994-10-07 1995-10-06 Антигипертриглицеридемическая композиция (варианты), способ ее получения, способ лечения или профилактики гипертриглицеридемии RU2166320C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24413694 1994-10-07
JP06-244136 1994-10-07

Publications (2)

Publication Number Publication Date
RU95117068A RU95117068A (ru) 1998-01-10
RU2166320C2 true RU2166320C2 (ru) 2001-05-10

Family

ID=17114301

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95117068/14A RU2166320C2 (ru) 1994-10-07 1995-10-06 Антигипертриглицеридемическая композиция (варианты), способ ее получения, способ лечения или профилактики гипертриглицеридемии

Country Status (11)

Country Link
EP (1) EP0705607A2 (show.php)
KR (1) KR960013370A (show.php)
CN (1) CN1128657A (show.php)
AU (1) AU703422B2 (show.php)
CA (1) CA2160092A1 (show.php)
FI (1) FI954773A7 (show.php)
HU (1) HUT73422A (show.php)
NO (1) NO308580B1 (show.php)
NZ (1) NZ280165A (show.php)
RU (1) RU2166320C2 (show.php)
TW (1) TW401301B (show.php)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2271808C2 (ru) * 2001-06-06 2006-03-20 Ф. Хоффманн-Ля Рош Аг Фармацевтическая композиция, включающая ингибитор липазы и жирнокислотный сложный эфир сахарозы

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) * 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
PT862562E (pt) * 1995-09-13 2001-11-30 Takeda Chemical Industries Ltd Compostos de benzoxazepina sua producao e utilizacao como agentes para reducao dos niveis de lipidos
AU3481497A (en) * 1996-06-11 1998-01-07 Zonagen, Inc. Chitosan drug delivery system
ATE309993T1 (de) 1997-04-21 2005-12-15 Takeda Pharmaceutical 4,1-benzoxazepine, ihre analoga, und ihre verwendung als somatostatin-agonisten
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
AP2000001929A0 (en) 1998-03-31 2000-09-30 Inst For Pharm Discovery Inc Substituted indolealkanoic acids.
US6207664B1 (en) 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
WO2000073284A2 (en) 1999-05-26 2000-12-07 Du Pont Pharmaceuticals Company 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
AU6420700A (en) * 1999-08-05 2001-03-05 Prescient Neuropharma Inc. Novel 1,4-benzodiazepine compounds and derivatives thereof
WO2002038180A1 (en) * 2000-11-09 2002-05-16 Takeda Chemical Industries, Ltd. High-density lipoprotein-cholesterol level elevating agent
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US20040204500A1 (en) * 2001-06-28 2004-10-14 Yasuo Sugiyama Preventives/remedies for organ functional disorders and organ dysfunction
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
EP1591120A4 (en) * 2003-01-28 2009-06-10 Takeda Chemical Industries Ltd RECEPTOR AGONISTS
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20090118255A1 (en) * 2004-08-09 2009-05-07 Takeda Pharmaceutical Company Limited Crp Lowering Agent
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
BRPI0811204A8 (pt) 2007-05-10 2015-09-22 Bristol Myers Squibb Co Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
WO2021226208A2 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153190A (en) * 1990-03-08 1992-10-06 Adir Et Compagnie Pyrrolo [1,2A] thieno [3,2-F] [1,4] diazepines
US5180717A (en) * 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
EP0579222A2 (en) * 1992-07-17 1994-01-19 Senju Pharmaceutical Co., Ltd. Lipid metabolism improving composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG82630A1 (en) * 1992-04-20 2001-08-21 Takeda Chemical Industries Ltd 4,1-benzoxazepin derivatives and their use
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
WO1995021834A1 (en) * 1994-02-09 1995-08-17 Takeda Chemical Industries, Ltd. Optically active 4,1-benzoxazepine derivatives useful as squalene synthase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180717A (en) * 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
US5153190A (en) * 1990-03-08 1992-10-06 Adir Et Compagnie Pyrrolo [1,2A] thieno [3,2-F] [1,4] diazepines
EP0579222A2 (en) * 1992-07-17 1994-01-19 Senju Pharmaceutical Co., Ltd. Lipid metabolism improving composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Машковский М.Д. Лекарственные средства. - М.: Медицина, 1986, ч.2, с.90. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2271808C2 (ru) * 2001-06-06 2006-03-20 Ф. Хоффманн-Ля Рош Аг Фармацевтическая композиция, включающая ингибитор липазы и жирнокислотный сложный эфир сахарозы

Also Published As

Publication number Publication date
CA2160092A1 (en) 1996-04-08
FI954773A7 (fi) 1996-04-08
HU9502918D0 (en) 1995-11-28
TW401301B (en) 2000-08-11
NO953961D0 (no) 1995-10-05
EP0705607A3 (show.php) 1996-05-08
HUT73422A (en) 1996-07-29
FI954773A0 (fi) 1995-10-06
KR960013370A (ko) 1996-05-22
NO308580B1 (no) 2000-10-02
NZ280165A (en) 1997-07-27
CN1128657A (zh) 1996-08-14
AU3308195A (en) 1996-04-18
EP0705607A2 (en) 1996-04-10
NO953961L (no) 1996-04-09
AU703422B2 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
EP0862562B1 (en) Benzoxazepine compounds, their production and use as lipid lowering agents
AU703422B2 (en) Antihypertriglyceridemic composition
US20080132483A1 (en) Agent for preventing or treating organ functional disorders and organ dysfunction
EP0645377B1 (en) Benzoxazepine derivatives useful as squalene synthetase inhibitors
CA2231052C (en) Benzoxazepine compounds, their production and use as lipid lowering agents
EP0567026A1 (en) 4,1-Benzoxazepin derivatives as squalene synthase inhibitors and their use in the treatment of hypercholesteremia and as fungicides
JPWO2007102531A1 (ja) 併用薬
US20080058310A1 (en) High-density lipoprotein-cholesterol level elevating agent
JP3479796B2 (ja) ベンゾオキサゼピン化合物
US20090209510A1 (en) Novel Method of Treating Hyperlipidemia
JP4138299B2 (ja) 高密度リポタンパク−コレステロール上昇剤
JPH08157369A (ja) トリグリセライド低下剤
EP1600166A1 (en) Skeletal muscle protecting agent
US20090118255A1 (en) Crp Lowering Agent
JPH0987260A (ja) 縮合環化合物とその用途
JP4021612B2 (ja) ベンゾオキサゼピン化合物
RU2170732C2 (ru) Производные 4,1-бензоксазепина
JP3764180B2 (ja) 縮合環化合物とその用途
JP2004315500A (ja) 骨格筋保護剤
JP2007332154A (ja) ベンゾオキサゼピン化合物
KR20080015395A (ko) 황색종 치료제